Year: 2025
Type: article
Abstract: CRISPR-Cas9 technology is profoundly revolutionizing adoptive cell immunotherapy in the field of cancer treatment, especially CAR-T and TCR-T cell therapy. The technology enables highly customized modification of T cells through precise gene editing, solving some of the challenges that exist in traditional therapies. This review mainly introduces the application progress of CRISPR-Cas9 in CAR-T and TCR-T therapy, as well as related technical principles, and provides reference for future adoptive cell immunotherapy for cancer and other related diseases. With more in-depth research and clinical practice, CRISPR-Cas9 is expected to become a sword in the field of cancer treatment, bringing significant improvements in long-term survival and fundamental improvements in quality of life to countless cancer patients, marking the arrival of a new era of personalized medicine. In summary, CRISPR-Cas9 technology is leading adoptive cell immunotherapy into a new stage of development with its unique advantages and excellent results, and constantly expanding the boundaries of the possibility of human victory over cancer.
Source: Theoretical and Natural Science
Author: Yuzhu Li
Institution: Beijing University of Chinese Medicine
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4407823094